Company intelligence / Profile preview
Imophoron
Bristol, England, United Kingdomimophoron.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Imophoron has developed the ADDomer™ platform—a thermostable, self‑assembling nanoparticle technology for rapid design and production of next-generation vaccines. The company’s most advanced program targets RSV and has completed preclinical proof-of-concept with GMP process development underway. Other programs include chikungunya and COVID-19 vaccine candidates. The technology also shows promise for therapeutic applications in oncology. No clinical results are available yet as all programs remain preclinical.
- Therapeutic areas
- OncologyInfectious Diseases
- Modalities
- Nanoparticle vaccinesprotein-based vaccines
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Global Brain investment partnershipMeiji Yasuda Life Insurance Company via Meiji Yasuda Future Innovation Fund L.P.Octopus VenturesScience Creates Ventures
Beyond the preview
Go deeper on Imophoron.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Imophoron.